98%
921
2 minutes
20
Aberrant DNA methyltransferase (DNA MTase) activity correlates with abnormal DNA methylation patterns observed in various cancers, establishing DNA MTase as a therapeutic target for early clinical diagnosis and anticancer/antimicrobial treatment. Current DNA MTase detection methods remain laborious and technically challenging. This study presents a label-free, single-molecule nanopore sensing strategy for sensitive Dam MTase detection utilizing a DNA-polyarginine (DNA-R5) probe. The unique oscillating pattern of DNA-R5 contributes specificity, while other DNA structures cannot output such signatures. Herein, transformation to oscillating signal occurred by Hairpin DNA-R5 releasing the single-strand DNA-R5 with subsequent Dam methylation and DpnI excision. Optimization of mutant protein positioning, hairpin loop length, pH-dependent charge maintenance, and voltage for electroosmosis balance was experimentally validated, with pH 8.0 at 140 mV identified as optimal for signal generation. The integrated use of magnetic beads can lower the Dam detection limit to 0.00005 U/mL. Validation in diluted human serum confirmed the assay implementation while penicillin inhibition studies demonstrated the platform's drug discovery potential. Our proposed approach shows promise for clinical diagnostics, with DNA-R5 serving as a versatile probe for future therapeutic target analysis, the next plan for larger-scale clinical trials was the testing of bacterial lysates in the patient's serum and track the Dam progress before and after drug treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bios.2025.117859 | DOI Listing |
Background: Nucleophosmin 1 (NPM1) mutations represent one of the most frequent genetic alterations in acute myeloid leukemia (AML). However, the prognostic significance of concurrent molecular abnormalities and clinical features in NPM1-mutated AML remains to be fully elucidated.
Methods: We retrospectively analyzed 73 adult AML patients with NPM1 mutations.
Background: Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive form of peripheral T-cell lymphoma, accounting for 1 - 2% of non-Hodgkin lymphomas. Diagnosis is challenging, and there is no established standard first-line treatment. This case report highlights a rare progression from AITL to therapy-related acute myeloid leukemia (AML-pCT) following cytotoxic chemotherapy.
View Article and Find Full Text PDFFront Immunol
September 2025
Department of Rheumatology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, China.
Purpose: This study aimed to investigate whether Jianpi-Zishen Formula (JPZS) modulates the Treg/Th17 balance in MRL/lpr mice through regulation of DNA methyltransferase 1 (DNMT1)-mediated forkhead box P3 (Foxp3) methylation, and to elucidate its potential mechanism for improving immune homeostasis in systemic lupus erythematosus (SLE).
Methods: Forty-eight female MRL/lpr mice were randomized into six groups (n=8/group): JPZS (low/medium/high doses), 5-aza-CdR (DNMT inhibitor), DC_517 (DNMT1 inhibitor), and model control. Eight C57BL/6 mice served as healthy controls.
Elife
September 2025
Harvard University Department of Chemistry and Chemical Biology, Cambridge, United States.
The insulator protein CTCF is essential for mediating chromatin loops and regulating gene expression. While it is established that DNA methylation hinders CTCF binding, the impacts of this methylation-sensitive CTCF binding on chromatin architecture and transcription are poorly defined. Here, we used a selective DNMT1 inhibitor (DNMT1i) to investigate the characteristics and functions of 'DNMT1i-specific' CTCF peaks resulting from global DNA demethylation.
View Article and Find Full Text PDFClin Epigenetics
August 2025
Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, F-44000, Nantes, France.
Background: DNA methyltransferase (DNMT) inhibitors are emerging as a promising class of agents for personalized and targeted cancer therapy, particularly in malignancies with limited therapeutic options such as glioblastoma (GB). In GB, the MGMT/DGKI methylation profile serves as a biomarker for stratifying patients by treatment response. Specifically, the MGMT/DGKI profile is associated with favorable outcomes, whereas the MGMT/DGKI profile correlates with poor outcome.
View Article and Find Full Text PDF